NASDAQ:STRO Sutro Biopharma (STRO) Stock Price, News & Analysis → 4x Better than Bitcoin (From Behind the Markets) (Ad) Free STRO Stock Alerts $5.65 +0.72 (+14.60%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$4.97▼$6.1350-Day Range$3.27▼$5.6552-Week Range$2.01▼$6.13Volume3.14 million shsAverage Volume1.09 million shsMarket Capitalization$352.79 millionP/E RatioN/ADividend YieldN/APrice Target$13.71 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Sutro Biopharma alerts: Email Address Sutro Biopharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside142.7% Upside$13.71 Price TargetShort InterestHealthy3.72% of Shares Sold ShortDividend StrengthN/ASustainability-0.70Upright™ Environmental ScoreNews Sentiment0.60Based on 33 Articles This WeekInsider TradingSelling Shares$60,925 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.47) to ($2.92) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.69 out of 5 starsMedical Sector71st out of 939 stocksBiological Products, Except Diagnostic Industry12th out of 158 stocks 3.5 Analyst's Opinion Consensus RatingSutro Biopharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $13.71, Sutro Biopharma has a forecasted upside of 142.7% from its current price of $5.65.Amount of Analyst CoverageSutro Biopharma has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted3.72% of the outstanding shares of Sutro Biopharma have been sold short.Short Interest Ratio / Days to CoverSutro Biopharma has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sutro Biopharma has recently decreased by 3.73%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSutro Biopharma does not currently pay a dividend.Dividend GrowthSutro Biopharma does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSutro Biopharma has received a 73.67% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Sutro Biopharma is -0.70. Previous Next 3.1 News and Social Media Coverage News SentimentSutro Biopharma has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 33 news articles for Sutro Biopharma this week, compared to 2 articles on an average week.Search Interest9 people have searched for STRO on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days.MarketBeat Follows7 people have added Sutro Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sutro Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $60,925.00 in company stock.Percentage Held by InsidersOnly 6.90% of the stock of Sutro Biopharma is held by insiders.Percentage Held by Institutions96.99% of the stock of Sutro Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Sutro Biopharma are expected to grow in the coming year, from ($3.47) to ($2.92) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sutro Biopharma is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sutro Biopharma is -3.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSutro Biopharma has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About Sutro Biopharma Stock (NASDAQ:STRO)Sutro Biopharma, Inc. operates as a clinical-stage oncology company. It develops site-specific and novel-format antibody drug conjugates (ADC) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. The company's product candidates include STRO-001, an ADC directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. Its pre-clinical product candidate STRO-003, a ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology; EMD Serono to develop ADCs for multiple cancer targets; and Astellas Pharma Inc. to develop ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.Read More STRO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart STRO Stock News HeadlinesMarch 29, 2024 | americanbankingnews.comQ1 2024 EPS Estimates for Sutro Biopharma, Inc. (NASDAQ:STRO) Decreased by HC WainwrightMarch 29, 2024 | americanbankingnews.comWedbush Comments on Sutro Biopharma, Inc.'s Q1 2024 Earnings (NASDAQ:STRO)March 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 28, 2024 | americanbankingnews.comSutro Biopharma's (STRO) Outperform Rating Reaffirmed at OppenheimerMarch 27, 2024 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Catalyst Pharma (CPRX)March 27, 2024 | markets.businessinsider.comNavigating 4 Analyst Ratings For Sutro BiopharmaMarch 27, 2024 | finance.yahoo.comSutro Biopharma Inc (STRO) Earnings: A Mixed Bag Amidst Strategic AdvancesMarch 27, 2024 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) to Post Q1 2025 Earnings of ($0.83) Per Share, Wedbush ForecastsMarch 29, 2024 | Behind the Markets (Ad)4x Better than Bitcoin4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.March 27, 2024 | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Receives "Market Outperform" Rating from JMP SecuritiesMarch 27, 2024 | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Given New $8.00 Price Target at WedbushMarch 27, 2024 | americanbankingnews.comSutro Biopharma (NASDAQ:STRO) Price Target Lowered to $12.00 at HC WainwrightMarch 26, 2024 | finanznachrichten.deSutro Biopharma, Inc.: Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesMarch 26, 2024 | markets.businessinsider.comTD Cowen Sticks to Its Buy Rating for Sutro Biopharma (STRO)March 26, 2024 | markets.businessinsider.comSutro Biopharma Buy Rating Affirmed on Strong Financials and Promising Clinical PipelineMarch 25, 2024 | investorplace.comSTRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023March 25, 2024 | globenewswire.comSutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated MilestonesMarch 23, 2024 | americanbankingnews.comSutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of "Buy" from AnalystsFebruary 10, 2024 | msn.comSutro Biopharma Expands Share Offering, Raises $129MJanuary 9, 2024 | markets.businessinsider.comSutro Biopharma: Hold Rating Maintained Amid Near-Term Uncertainties and Market Potential AmbiguitiesJanuary 6, 2024 | markets.businessinsider.comBuy Rating Justified: Sutro Biopharma’s Luvelta Shows Promise in PROC Treatment and BeyondJanuary 4, 2024 | finance.yahoo.comSutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADCDecember 29, 2023 | benzinga.comSutro Biopharma Stock (NASDAQ:STRO) Dividends: History, Yield and DatesDecember 18, 2023 | finance.yahoo.comSutro Biopharma, Inc.'s (NASDAQ:STRO) Share Price Boosted 48% But Its Business Prospects Need A Lift TooDecember 14, 2023 | finance.yahoo.comSutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024December 12, 2023 | markets.businessinsider.comBuy Rating for Sutro Biopharma: Promising Clinical Developments and Strategic Financial StrengthDecember 11, 2023 | finance.yahoo.comSutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023See More Headlines Receive STRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sutro Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/29/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:STRO CUSIPN/A CIK1382101 Webwww.sutrobio.com Phone(650) 392-8412FaxN/AEmployees298Year FoundedN/APrice Target and Rating Average Stock Price Target$13.71 High Stock Price Target$25.00 Low Stock Price Target$8.00 Potential Upside/Downside+142.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,200,000.00 Net Margins-69.47% Pretax Margin-57.63% Return on Equity-71.42% Return on Assets-24.92% Debt Debt-to-Equity RatioN/A Current Ratio4.50 Quick Ratio5.18 Sales & Book Value Annual Sales$153.73 million Price / Sales2.29 Cash FlowN/A Price / Cash FlowN/A Book Value$3.78 per share Price / Book1.49Miscellaneous Outstanding Shares62,440,000Free Float58,134,000Market Cap$352.79 million OptionableOptionable Beta0.95 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. William J. Newell J.D. (Age 66)CEO & Director Comp: $1.07MMs. Jane Chung R.Ph. (Age 52)President & COO Comp: $934.64kDr. James R. Swartz DScPh.D., Sc.D., FounderMr. Edward C. Albini M.B.A (Age 66)CFO & Secretary Comp: $596.4kDr. Venkatesh Srinivasan Ph.d.Chief Technical Operations OfficerDr. Hans-Peter Gerber Ph.D.Chief Scientific OfficerMr. David Pauling J.D.M.A., General CounselMs. Linda A. Fitzpatrick (Age 67)Chief People & Communications Officer Comp: $595.79kDr. Nicki Vasquez Ph.D. (Age 61)Chief Portfolio Strategy & Alliance Officer Dr. Anne Elizabeth Borgman-Hagey M.D. (Age 55)Chief Medical Officer More ExecutivesKey CompetitorsGritstone bioNASDAQ:GRTSCompass TherapeuticsNASDAQ:CMPXCentury TherapeuticsNASDAQ:IPSCScilexNASDAQ:SCLXCoherus BioSciencesNASDAQ:CHRSView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 21,238 shares on 3/11/2024Ownership: 4.742%Virtu Financial LLCBought 16,766 shares on 2/26/2024Ownership: 0.028%Vanguard Group Inc.Bought 21,238 shares on 2/15/2024Ownership: 4.742%Parkman Healthcare Partners LLCBought 20,263 shares on 2/15/2024Ownership: 1.973%Nuveen Asset Management LLCBought 3,583 shares on 2/15/2024Ownership: 0.354%View All Insider TransactionsView All Institutional Transactions STRO Stock Analysis - Frequently Asked Questions Should I buy or sell Sutro Biopharma stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STRO shares. View STRO analyst ratings or view top-rated stocks. What is Sutro Biopharma's stock price target for 2024? 7 equities research analysts have issued 12-month price objectives for Sutro Biopharma's shares. Their STRO share price targets range from $8.00 to $25.00. On average, they anticipate the company's share price to reach $13.71 in the next twelve months. This suggests a possible upside of 142.7% from the stock's current price. View analysts price targets for STRO or view top-rated stocks among Wall Street analysts. How have STRO shares performed in 2024? Sutro Biopharma's stock was trading at $4.29 at the beginning of the year. Since then, STRO shares have increased by 31.7% and is now trading at $5.65. View the best growth stocks for 2024 here. When is Sutro Biopharma's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our STRO earnings forecast. How were Sutro Biopharma's earnings last quarter? Sutro Biopharma, Inc. (NASDAQ:STRO) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.02. The company had revenue of $8.52 million for the quarter, compared to the consensus estimate of $8.85 million. Sutro Biopharma had a negative trailing twelve-month return on equity of 71.42% and a negative net margin of 69.47%. What ETF holds Sutro Biopharma's stock? Simplify Propel Opportunities ETF holds 120,000 shares of STRO stock, representing 0.53% of its portfolio. What is William J. Newell's approval rating as Sutro Biopharma's CEO? 11 employees have rated Sutro Biopharma Chief Executive Officer William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among the company's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Sutro Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS) and AbbVie (ABBV). When did Sutro Biopharma IPO? Sutro Biopharma (STRO) raised $75 million in an initial public offering on Thursday, September 27th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Sutro Biopharma's major shareholders? Sutro Biopharma's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.74%), Vanguard Group Inc. (4.74%), Franklin Resources Inc. (4.53%), Kynam Capital Management LP (3.28%), Parkman Healthcare Partners LLC (1.97%) and Dimensional Fund Advisors LP (1.87%). Insiders that own company stock include Brunilda Shtylla, Nicki Vasquez and William J Newell. View institutional ownership trends. How do I buy shares of Sutro Biopharma? Shares of STRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:STRO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 Media“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & CompanyAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.